Orient Europharma Co (ROCO:4120) EV-to-EBITDA : 11.30 (As of Sep. 22, 2024)

Orient Europharma Co EV-to-EBITDA Chart

Orient Europharma Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					9.94	10.37	18.59	-104.69	11.62

Orient Europharma Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EV-to-EBITDA	Get a 7-Day Free Trial															-68.23	83.96	11.62	15.75	11.84

Competitive Comparison of Orient Europharma Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orient Europharma Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Orient Europharma Co's EV-to-EBITDA falls into.

Orient Europharma Co EV-to-EBITDA Calculation

Orient Europharma Co's EV-to-EBITDA for today is calculated as:

Orient Europharma Co's current Enterprise Value is NT$7,475 Mil.
Orient Europharma Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$661 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co  (ROCO:4120) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Orient Europharma Co's PE Ratio for today is calculated as:

Orient Europharma Co's share price for today is NT$49.70.
Orient Europharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.670.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Orient Europharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Orient Europharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Orient Europharma Co Business Description